Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Methods for Using Reutercyclin Based Antibiotics to Treat Clostridium difficile Infections
|Description||St. Jude researchers have shown that reutercyclin and its derivatives can be used to treat C. difficile. Unlike current treatments, reutercyclin lacks toxicity against gut epithelial cells, which allows for oral administration. These compounds also kill stationary phase C. difficile, which may hinder the formation of spores and lower potential relapse of infection. .|
|Keywords||Hospital-acquired C. difficile-associated diarrhea, CDAD|
|Published Applications||Available upon request under confidentiality|
|Related Scientific References||Hurdle, Julian G., et al. Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. J. Antimicrobial Chemotherapy. (2011) 66(8): 1773-1776|
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: November 2011